Photometics has developed a uniquely effective therapy for Basal Cell Carcinoma, the most common form of skin cancer, affecting more than 1 million Americans annually.Photometic's patented "selective photo-apoptosis" technology is based on decades of research into differential infrared absorption, determining and delivering the precise characteristics of light energy needed to kill cancer cells while leaving surrounding tissues intact.